Every entry links to the official document on fda.gov and reproduces the product names exactly as FDA writes them. Entries are never described as resolved without authoritative evidence, and an affiliate relationship never removes or softens an entry.
Several firms did not sell peptides under their drug names. FDA's letters record products offered as “GLP-2 TZ”, “GLP-3 RT”, “GLP-1-S” and “GLP-1-R peptide” — code for tirzepatide, retatrutide and semaglutide. One firm's own site called retatrutide a “GLP-1-R peptide”; another sold “GLP-2-T”.
The naming did not change how FDA treated the products. If a seller lists items under codes rather than the substance name, that is a documented characteristic of firms that have received warning letters — and it makes a certificate of analysis impossible to match to a product.
A warning letter states FDA's position at the date it was issued. It is not a court finding, and it does not by itself establish that a company is still operating in the way the letter describes. Where a firm has responded or corrected, that would appear in a separate, later document — and because we have no authoritative evidence of resolution for any entry above, none is described as resolved.
What a letter does establish is that FDA reviewed a specific website on a specific date and reached a stated conclusion about specific products. That is the fact we record — nothing more.
